Hepatocellular carcinoma(HCC),frequently diagnosed at advanced stages in China due to insidious onset,faces a dismal prognosis with limited surgical feasibility.The advent of immunotherapy,particularly immune checkpoint inhibitors(ICIs),introduces novel therapeutic prospects,albeit with variable efficacies.The combination of ICIs with various therapeutic strategies is increasingly recognized as a critical approach in the management of advanced HCC.This article reviews recent advances in ICIs for advanced hepatocellular carcinoma and discusses the future prospects of immunotherapy.
维普
万方数据